Adjuvant ovarian function suppression and cognitive function in women with breast cancer

Autor: Frances M. Boyle, Jürg Bernhard, Tim A. Ahles, Alan S. Coates, Susan M. Domchek, Simon Spazzapan, Khalil Zaman, Richard D. Gelber, Gini F. Fleming, Prudence A. Francis, Meredith M. Regan, E Abdi, John F. Forbes, Yang Feng, Karin Ribi, Per Karlsson, Daniel R. Budman, Paul Maruff, Meritxell Bellet, Fabio Puglisi, Karen N. Price, Kelly-Anne Phillips
Jazyk: angličtina
Rok vydání: 2016
Předmět:
Oncology
Cancer Research
medicine.medical_specialty
Antineoplastic Agents
Hormonal
medicine.drug_class
medicine.medical_treatment
ovarian function
Breast Neoplasms
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Breast cancer
breast cancer
Cognition
Exemestane
Internal medicine
medicine
Clinical endpoint
Humans
skin and connective tissue diseases
GnRH agonist
cognitive function
Chemotherapy
premenopausal
tamoxifen
business.industry
Aromatase Inhibitors
medicine.disease
Menopause
chemistry
quality of life
Estrogen
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Clinical Study
Adjuvants
Immunologic
Adult
Antineoplastic Agents
Hormonal/therapeutic use
Breast Neoplasms/complications
Breast Neoplasms/drug therapy
Female
Middle Aged
Ovary/metabolism
Premenopause
Quality of Life
Tamoxifen/therapeutic use
business
Adjuvant
exemestane
030217 neurology & neurosurgery
Tamoxifen
medicine.drug
Zdroj: British Journal of Cancer
British journal of cancer, vol. 114, no. 9, pp. 956-964
ISSN: 1532-1827
0007-0920
Popis: Background: To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer. Methods: The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test. Results: Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., −0.21±0.92 vs −0.04±0.49, respectively, P=0.71, effect size=−0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics. Conclusions: The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.
Databáze: OpenAIRE
Externí odkaz: